Abstract
Myocardial infarction (MI) remains a leading cause of mortality and morbidity, while percutaneous coronary intervention (PCI) has become the most commonly performed invasive therapeutic procedure among patients with cardiovascular disease 1 . Aspirin, a non-selective cycloxegenase inhibitor, and clopidogrel, a platelet P2Y12 receptor inhibitor, are universally administered to patients undergoing a percutaneous revascularization because of their proven efficacy in reducing major adverse cardiovascular events, making them one of the most frequently prescribed drugs worldwide. Despite clear improvements in platelet-directed therapy, thrombotic events remain common, both early and late after PCI with or without a stent implantation 2,3
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
